Keros Therapeutics (NASDAQ:KROS) Shares Gap Down - Here's What Happened

Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) shares gapped down prior to trading on Monday . The stock had previously closed at $15.04, but opened at $14.20. Keros Therapeutics shares last traded at $14.60, with a volume of 556,990 shares changing hands.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on KROS shares. Wells Fargo & Company reduced their price target on Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Thursday, February 27th. Wedbush restated a "neutral" rating and issued a $15.00 price target on shares of Keros Therapeutics in a research note on Friday, May 30th. Scotiabank decreased their price target on shares of Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating on the stock in a research note on Monday, May 12th. Truist Financial decreased their price target on shares of Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating on the stock in a research note on Wednesday, April 9th. Finally, HC Wainwright decreased their price target on shares of Keros Therapeutics from $40.00 to $25.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Six equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $37.00.

Keros Therapeutics Stock Performance

The company has a market cap of $574.91 million, a price-to-earnings ratio of -2.72 and a beta of 1.31. The business has a fifty day moving average price of $13.44 and a 200 day moving average price of $17.76.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $3.62 earnings per share for the quarter, beating analysts' consensus estimates of ($0.01) by $3.63. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company had revenue of $211.25 million for the quarter, compared to the consensus estimate of $84.62 million. During the same period last year, the company posted ($1.21) EPS. As a group, equities analysts anticipate that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

Insider Activity

In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc bought 934,258 shares of the business's stock in a transaction that occurred on Wednesday, April 9th. The shares were acquired at an average cost of $10.13 per share, for a total transaction of $9,464,033.54. Following the transaction, the insider now directly owns 4,392,737 shares in the company, valued at approximately $44,498,425.81. This represents a 27.01% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 20.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Keros Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC boosted its position in Keros Therapeutics by 7,690.3% during the 1st quarter. GAMMA Investing LLC now owns 2,415 shares of the company's stock worth $237,000 after buying an additional 2,384 shares during the period. FNY Investment Advisers LLC acquired a new stake in Keros Therapeutics during the 1st quarter worth approximately $25,000. CWM LLC increased its stake in shares of Keros Therapeutics by 10,157.7% in the first quarter. CWM LLC now owns 2,667 shares of the company's stock valued at $27,000 after buying an additional 2,641 shares during the period. AlphaQuest LLC increased its stake in shares of Keros Therapeutics by 469.0% in the fourth quarter. AlphaQuest LLC now owns 3,596 shares of the company's stock valued at $57,000 after buying an additional 2,964 shares during the period. Finally, Virtus ETF Advisers LLC increased its stake in shares of Keros Therapeutics by 107.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company's stock valued at $61,000 after buying an additional 1,998 shares during the period. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.